Polymyxin B-Based Hemoperfusion for the Treatment of Endotoxic Shock

Guest Editors
Claudio Ronco, Vicenza
Antonio Artigas, Sabadell
Massimo Antonelli, Rome
The presence of endotoxin in the bloodstream is the consequence of an immunological response triggered by bacterial invasion of the host. This condition leads to altered cardiovascular function, lung dysfunction and acute kidney injury. Removing as much as possible of the circulating endotoxin is therefore imperative to mitigate its biological and clinical effects at the cellular, tissue and organ levels. The publication at hand summarizes the basic mechanisms, rationale and clinical results of a new therapeutic approach that promises to attain this goal: It consists of a specific hemoperfusion process that utilizes cartridges with immobilized polymyxin B in an extracorporeal circuit.

Containing contributions by renowned researchers, this book represents a milestone in the field of extracorporeal therapies in sepsis. It will be a valuable reference work for both basic scientists and clinical professionals who want to keep abreast of current developments.

Contents

Preface: Ronco, C.; Piccinni, P.; Rosner, M.H.

Endotoxemia: Pathophysiological Background

Endotoxin in the Pathogenesis of Sepsis: Marshall, J.C.

Endotoxins and Other Sepsis Triggers: Opal, S.M.

Extracorporeal Endotoxin Removal:

Theory and Technology


Extracorporeal Removal of Endotoxin:

The Polymyxin B-Immobile Fiber Cartridge:

Tani, T.; Shoji, H.; Guadagni, G.; Pergo, A.


Endotoxin Removal in Septic Shock in Clinical Settings

Endotoxin Removal by Polymyxin B-Immobilized Cartridge Inactivates Circulating Proapoptotic Factors: Martin, E.L.; Ranieri, V.M.

Polymyxin B Hemoperfusion and Endotoxin Removal: Lessons from a Review of the Literature: Cruz, D.N.; de Cal, M.; Piccinni, P.; Ronco, C.

PMX Endotoxin Removal in the Clinical Practice: Results from the EUPHAS Trial: Antonelli, M.; Fumagalli, R.; Cruz, D.N.; Brienza, N.; Giunta, F. on behalf of the EUPHAS Study Group

Early Management of Endotoxemia Using the Endotoxin Activity Assay and Polymyxin B-Based Hemoperfusion: Novelli, G.; Ferretti, G.; Ruberto, F.; Morabito, V.; Pugliese, F.

Endotoxin Activity Level and Septic Shock:

A Possible Role for Specific Anti-Endotoxin Therapy?: Monti, G.; Bottiroli, M.; Pizzilli, G.; Minnini, M.; Terzi, V.; Vecchi, I.; Gesu, G.; Briasci, P.; Vesconi, S.; Casella, G.

Endotoxin Removal: Building the Evidence


Endotoxin Removal: How Far from the Evidence? The EUPHAS 2 Project: Martin, E.L.; Cruz, D.N.; Monti, G.; Casella, G.; Vesconi, S.; Ranieri, V.M.; Ronco, C.; Antonelli, M.

Orders may be placed with any bookshop, subscription agency, directly with the publisher or through a Karger distributor.
Critical Care Nephrology

Stefan D. Anker, Berlin
Massimo Antonelli, Rome
Ian C. Baldwin, Heidelberg, Vic.
Rinaldo Bellomo, Melbourne, Vic.
Guido Bertolini, Ranica
W. Kline Bolton, Charlottesville, Va.
Joseph V. Bonventre, Boston, Mass.
John Burkart, Winston-Salem, N.C.
Lakhmir Chawla, Washington, D.C.
Maria Rosa Costanzo, Naperville, Ill.
Dinna N. Cruz, Vicenza
Andrew Davenport, London
Salvatore Di Somma, Rome
Enrico Fiaccadori, Parma
Mihai Gheorghiade, Chicago, Ill.
Stuart L. Goldstein, Cincinnatti, Ohio
Michael Haase, Magdeburg
Patrick Honoré, Brussels
Eric Hoste, Ghent
Nevin Katz, Washington, D.C.

Peritoneal Dialysis

Richard Amerling, New York, N.Y.
George L. Bakris, Chicago, Ill.
Jordi Bover, Barcelona
Joanne M. Bargman, Toronto, Ont.
Edwina A. Brown, London
Ricardo Correa-Rotter, Mexico
Carlo Crepaldi, Vicenza
Olivier Devuyst, Zurich
Mariano Feriani, Mestre
Fredric Finkelstein, New Haven, Conn.
Guido Garosi, Siena
David Goldsmith, London
Roger N. Greenwood, Stevenage
Olof Heimburger, Stockholm
Achim Joerres, Berlin
Raymond Krediet, Amsterdam
Zhi-Hong Liu, Nanjing
Francesca Martin, Vicenza
Rajnish Mehrotra, Seattle, Wash.
Piergiorgio Messa, Milan
Andrew Mooney, Leeds
K. Shivanand Nayak, Hyderabad
Karl D. Nolph, Columbia, Mo.

Hemodialysis

Pedro Aljama, Cordoba
Stefano Bianchi, Arezzo
Prem K.G. Chandran, Des Moines, Iowa
John Collins, Auckland
Rosanna Coppo, Turin
Adrian A. Covic, Iasi
Mario Cozzolino, Milan
Angel M. de Francisco, Santander
Francesco Galli, Perugia
Victor Gura, Beverly Hills, Calif.
Stephan von Haehling, Berlin
Jorgen Hegbrant, Lund
Nicholas Hoenich,
  Newcastle upon Tyne
Alp Ikizler, Nashville, Tenn.
Hideki Kawanishi, Hiroshima
William F. Keane, Minneapolis, Minn.
John A. Kellum, Pittsburgh, Pa.
Peter Kotanko, New York, N.Y.
Martin K. Kuhlmann, Berlin
Nathan W. Levin, New York, N.Y.
Francesco Locatelli, Lecco
Peter McCullough, Novi, Mich.
Madhukar Misra, Columbia, Mo.

(Continued on next page)
(Continued)

**Critical Care Nephrology**
Norbert Lameire, Ghent  
Alan Maisel, San Diego, Calif.  
Alexandre Mebazaa, Paris  
Ravindra L. Mehta, San Diego, Calif.  
Bruce Molitoris, Indianapolis, Ind.  
Patrick T. Murray, Dublin  
Federico Nalesso, Vicenza  
Mark Okusa, Charlottesville, Va.  
Heleen M. Oudemans-Van Straaten, Amsterdam  
Paul M. Palevsky, Pittsburgh, Pa.  
Didier Payen, Paris  
Pasquale Piccinni, Vicenza  
Piotr Ponikowski, Wroclaw  
John R. Prowle, London  
V. Marco Ranieri, Turin  
Zaccaria Ricci, Rome  
Marie Schetz, Leuven  
Andrew Shaw, Durham, N.C.  
Shigehiko Uchino, Tokio  
David Warnock, Birmingham, Ala.

**Peritoneal Dialysis**
Miguel Perez Fontan, A Coruña  
Beth M. Piraino, Pittsburgh, Pa.  
Giuseppe Remuzzi, Bergamo  
Miguel C. Riella, Curitiba  
Bengt Rippe, Lund  
Jean-Philippe Ryckelyn, Caen  
Dirk G. Struijk, Amsterdam  
Isaac Teitelbaum, Aurora, Colo.  
Josep Teixido-Planas, Badalona  
Wim Van Biesen, Ghent  
Christian Verger, Pontoise  
Enrico E. Verrina, Genoa  
Janusz Witowski, Poznan

**Hemodialysis**
Allen R. Nissenson, Los Angeles, Calif.  
Mark Okusa, Charlottesville, Va.  
Vincenzo Panichi, Pisa  
Mauro Pittiruti, Rome  
Michael Rocco, Winston-Salem, N.C.  
Mitchell Rosner, Charlottesville, Va.  
Antonio Santoro, Bologna  
Daniel Schneditz, Graz  
Stanley Shaldon, Monaco  
Sergio Stefoni, Bologna  
Peter Stenvinkel, Stockholm  
Andrea Stopper, Bad Homburg  
Giro Tetta, Bad Homburg  
Angela Y. Wang, Hong Kong  
Richard Ward, Louisville, Ky.  
Dick de Zeeuw, Groningen  
Robert Zietse, Rotterdam  
Carmine Zoccali, Reggio Calabria
Aims and Scope
Practical information on hemodialysis, hemofiltration, peritoneal dialysis and plasma filtration is featured in this journal. Recognizing the critical importance of equipment and procedures, particular emphasis has been placed on reports, drawn from a wide range of fields, describing technical advances and improvements in methodology. Papers reflect the search for cost-effective solutions which increase not only patient survival but also comfort through prevention or correction of undesirable effects. Advances in vascular access and blood anticoagulation, problems associated with exposure of blood to foreign surfaces and acute-care nephrology, including continuous therapies, also receive attention. Nephrologists, intensivists and hospital staff involved in dialysis, apheresis and immunoadsorption for acute and chronic solid organ failure will find this journal useful and informative.

Submission
Manuscripts written in English are considered and should be submitted online at www.karger.com/bpu

Should you experience problems with your submission, please contact

Editorial Office 'Blood Purification'
S. Karger AG
PO Box
CH-4009 Basel (Switzerland)
Tel. +41 61 306 1356
Fax +41 61 306 1434
E-Mail bpu@karger.com

Conditions
All manuscripts are subject to editorial review. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication implies transfer of the copyright from the authors to the publisher upon acceptance. Accepted papers become the permanent property of the publisher. It is the author’s responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Conflicts of Interest
Authors are required to disclose any sponsorship or funding arrangements relating to their research and all authors should disclose any possible conflicts of interest. Conflict of interest statements will be published at the end of the article.

Ethics
Published research must comply with the guidelines for human studies and animal welfare regulations. Authors should state that subjects have given their informed consent and that the study protocol has been approved by the institute's committee on human research. Further, they should also state that animal experiments conform to institutional standards.

Categories of Manuscripts
(Law limits include tables, illustrations and references)

• Original Papers are full-length research papers which will be considered for the journal. Articles cover topics relevant to blood cleansing studies (max. 2,500 words).

• In-Depth Reviews are comprehensive, state-of-the-art papers (systematic reviews or meta-analyses) on important clinical problems of hemodialysis, hemofiltration, peritoneal dialysis and plasma filtration. In-Depth Reviews may be invited by the Editor or they may be unsolicited (max. 5,000 words), although in the latter, we ask the author to send the Editor a short outline first (300–400 words) to ensure that a review on a similar subject has not already been commissioned. Manuscripts will be assessed in-house and those judged suitable will be peer-reviewed before an editorial decision is made.

• Editorials are usually invited by the Editor (max. 1,000 words). Please send suggestions to the Editor.

• Methods in Blood Purification papers dealing with methodological issues in blood purification studies (e.g. recruitment, exclusion and inclusion criteria, methodological evaluation, novel approaches to clinical trials, statistics analyses and follow-up problems and solutions), particularly with regard to on-going large-population based studies, controlled clinical trials, cohort and case-control studies are welcome (max. 5,000 words).

• Letters to the Editor and Opinions. Manuscripts of max. 500 words, 1 figure or table and max. 10 references are considered for publication provided they describe a novel observation or add pertinent new information.

Arrangement

Title page: The first page of each paper should indicate the title, the authors’ names, the institute where the work was conducted, and a short title for use as running head.

Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address.

Key words: Please supply 3–10 key words in English that reflect the content of the paper.

Abstract: Each paper needs an abstract in English of not more than 150 words. It should be structured as follows:

Background/Aims: What is the major problem that prompted the study?

Methods: How was the study performed?

Results: Most important findings?

Conclusion: Most important conclusion?

Abstract of In-Depth Reviews: Should be divided into the following subsections: Background, Summary and Key Messages. The Background should provide a brief clinical context for the review and is followed by the Summary, which should include a concise description of the main topics covered in the text. The Key Messages encapsulate the main conclusions of the review.

Footnotes: Avoid footnotes.

Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate pages. Tables require a heading and figures a legend, also prepared on a separate page. For the reproduction of illustrations, only good drawings are acceptable; negatives or photocopies cannot be used. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180 × 223 mm) or provide crop marks. Electronically submitted b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi.

Color illustrations

Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 800.– per page.

References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples


(b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.


Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

Digital Object Identifier (DOI)
S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published

© 2014 S. Karger AG, Basel

KARGER
E-Mail karger@karger.com
www.karger.com

The Guidelines for Authors are available at: www.karger.com/bpu_Guidelines
online without volume or issue information. More information can be found at www.doi.org.

Supplementary Material
Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 Mb in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpeg).

Author’s Choice™
Karger’s Author’s Choice™ service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.–, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.

NIH-Funded Research
The U.S. National Institutes of Health (NIH) mandates under the NIH Public Access Policy that final, peer-reviewed manuscripts appear in its digital database within 12 months of the official publication date. As a service to authors, Karger submits the final version of your article on your behalf to PubMed Central. For those selecting our premium Author’s Choice™ service, we will send your article immediately upon publishing, accelerating the accessibility of your work without the usual embargo. More details on NIH’s Public Access Policy is available at http://publicaccess.nih.gov/FAQ.htm#a1

Self-Archiving
Karger permits authors to archive their pre-prints (i.e. pre-refereeing) or post-prints (i.e. final draft post-refereeing) on their personal or institution’s servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher’s version, and must acknowledge the publisher’s copyright. Authors selecting Karger’s Author’s Choice™ feature, however, are also permitted to archive the final, published version of their article, which includes copyediting and design improvements as well as citation links.

Page Charges
There are no page charges for papers of 2 printed pages. Each additional complete or partial page will be charged to the author at a rate of CHF 325.00 per page.

Proofs
Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations made in proofs, other than the correction of printer’s errors, are charged to the author.

Reprints
Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.

For the first time ever, both editions of Andreas Vesalius’ masterpiece “De Humani Corporis Fabrica” are accessible in the English language. They were critically compared and published in a modern layout transforming the Renaissance anatomical atlas for the 21st-century reader. More than 5,000 annotations cover anything from antique sources over Galenic references to the medical and cultural background of Vesalius’ time. To enable the reader and medical student to really study Vesalius’ woodcut illustrations, the images were digitally enhanced and often enlarged to feature his painstaking work of marking each pertinent anatomical part with characters. All over Vesalius’ descriptive text, the standard Latin Nomina Anatomica and Terminologia Anatomica provide the reader with the modern medical terminology.

For more information and easy ordering, please visit www.vesalius-fabrica.com
Adsorptive Dialysis Membranes
Clinical Potentials and Removal Principles

Editors
Thierry Hannedouche
Thierry Krummel
Antonio Santoro

Contents
- Editorial Comment
- Clinical Potentials of Adsorptive Dialysis Membranes: Krummel, T.; Hannedouche, T.
- The Double Polymethylmethacrylate Filter (DELETE System) in the Removal of Light Chains in Chronic Dialysis Patients with Multiple Myeloma: Santoro, A.; Grazia, M.; Mancini, E.
- Removal of Protein-Bound Uraemic Toxins by Haemodialysis: Niwa, T.
- Prurigo Nodularis and Dialyzer Membrane: Goeksel, T.; Xie, W.; Ritzerfeld, M.; Heidenreich, S.; Mann, H.
- Editorial Comment
- New Insights in End-Stage Renal Disease Therapies: From Dialysis to Apheresis by Means of Membrane Characteristics: Santoro, A.
- Adsorption Dialysis: From Physical Principles to Clinical Applications: Aucella, F.; Gesuete, A.; Vigilante, M.; Prencipe, M.
- Adsorption Techniques: Dialysis Sorbents and Membranes: Perego, A.F.
Contents

See the journal website for contents
The expert source of research and practice for nephrologists, cardiologists and critical care physicians

Blood Purification

Editor-in-Chief
C. Ronco, Vicenza

Assistant Editor
S. Chiaramonte, Vicenza

More information at www.karger.com/bpu

- Pay-per-View and Subscriber Access to Full Text
- Full Table of Contents
- Full Editorial Board
- Free Abstracts and Selected Articles
- Online Sample Issue
- Submission/Guidelines for Authors
- Subscription Details
- Free Alert Service
- Online Library Recommendation

Selected contributions

- Vascular Calcifications, Arterial Aging and Arterial Remodeling in ESRD: London, G.M.; Pannier, B.; Marchais, S.J. (Fleury-Mérogis)
- Reasons for the Lack of Salutary Effects of Cholesterol-Lowering Interventions in End-Stage Renal Disease Populations: Vaziri, N.D. (Irvine, Calif.);
  Norris, K.C. (Los Angeles, Calif.)
- Emerging Clinical Evidence on Online Hemodiafiltration: Does Volume of Ultrafiltration Matter?: Canaud, B. (Bad Homburg/Montpellier);
  Bowry, S.K. (Bad Homburg)
  Appel, A.S. (New York, N.Y.)
- Hydrodynamic Analysis of the Miniaturized Hemofilter for a Wearable Ultrafiltration Device: Ronco, C. (Vicenza);
  Kim, J.C. (Vicenza/Seoul);
  Garzotto, F. (Vicenza);
  Ronco, C. (Vicenza);
  Bellini, C.; Broglia, M. (Medolla);
  Nalesso, F. (Vicenza)
- Advanced Glycation End Products and β2-Microglobulin as Predictors of Carpal Tunnel Syndrome in Hemodialysis Patients: Busch, M.;
  Schwencky, A.; Franke, S.;
  Stein, G.; Wolf, G. (Jena)
  Yezzi, A.S. (Madison, Wis.);
  Tumlin, J. (Charitaroopa, Tenn.);
  Humes, H.D. (Ann Arbor, Mich.)
- Safe Use of Citric Acid-Based Dialysate and Heparin Removal in Postdilution Online Hemodiafiltration: Aniort, J.; Petitclerc, T.; Créput, C. (Paris)

Practical information on hemodialysis, hemofiltration, peritoneal dialysis and apheresis is featured in this journal. Recognizing the critical importance of equipment and procedures, particular emphasis has been placed on reports, drawn from a wide range of fields, describing technical advances and improvements in methodology. Papers reflect the search for cost-effective solutions which increase not only patient survival but also patient comfort and disease improvement through prevention or correction of undesirable effects. Advances in vascular access and blood anticoagulation, problems associated with exposure of blood to foreign surfaces and acute-care nephrology, including continuous therapies, also receive attention. Nephrologists, internists, intensivists and hospital staff involved in dialysis, apheresis and immunoadsorption for acute and chronic solid organ failure will find this journal useful and informative. Blood Purification also serves as a platform for multidisciplinary experiences involving nephrologists, cardiology and critical care physicians in order to expand the level of interaction between different disciplines and specialties.
Polymyxin B-Based Hemoperfusion for the Treatment of Endotoxic Shock

1 Preface
Ronco, C. (Vicenza); Artigas, A. (Sabadell); Antonelli, M. (Rome)

2 State of the Art in the Clinical Treatment of Endotoxic Shock
Artigas, A. (Sabadell); Piccinni, P. (Vicenza)

5 Endotoxin Removal: History of a Mission
Ronco, C. (Vicenza)

9 New Trends in Polymyxin B Hemoperfusion: From 2006 to 2013
Cruz, D.N. (San Diego, Calif.)

14 Endotoxin Removal: Bringing the Mission to North America
Foster, D.; Klein, D.J.; Guadagni, G.; Walker, P.M. (Toronto, Ont.)

18 Future Options for (Economically) Sustainable Research in Sepsis
Romay, E.; Ferrer, R. (Terrassa)

22 Polymyxin B Hemoperfusion in Clinical Practice: The Picture from an Unbound Collaborative Registry
The Early Use of Polymyxin B Hemoperfusion in the Abdominal Sepsis 2 (EUPHAS2) Collaborative Group

26 Author Index/Subject Index